|Bid||1.91 x 15500|
|Ask||2.04 x 3900|
|Day's Range||1.60 - 1.68|
|52 Week Range||1.47 - 27.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.38|
Law Offices of Howard G. Smith commences an investigation on behalf of Axovant Sciences Ltd. investors concerning the Company and its officers’ possible violations of federal securities laws.
Axovant Sciences made sweeping changes to its top ranks as the company struggles to regain its footing after abandoning its banner Alzheimer’s drug
Axovant Sciences Ltd. shares slid 21% in premarket trade Monday, after the company said Chief Executive David Hung and Chief Operating Officer Marion McCourt are leaving the company to pursue other opportunities. ...
Axovant Chief Operating Officer Marion McCourt and three directors on the company's board also stepped down. The departures come after Axovant stopped developing its lead drug, intepirdine, following the failure of two trials testing it as a treatment for Alzheimer's disease and dementia. "There is plenty of work to be done," incoming Axovant CEO Pavan Cheruvu said on a call with analysts.
David Hung resigns as CEO and continues as scientific advisor to Roivant family of companies Dr. Pavan Cheruvu appointed as CEO of Axovant Dr. Roger Jeffs, former President and co-CEO of United Therapeutics, ...
Axovant Sciences Ltd (NASDAQ: AXON )'s announcement this week that its lead drug candidate intepirdine failed in a late-stage trial comes after the stock lost 90 percent of its value over the past three ...
Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.
Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
BASEL, Switzerland, Jan. 09, 2018-- Axovant Sciences today announced a correction to the data related to the Company’ s investigational drug nelotanserin previously reported in its January 8, 2018 press ...
Efforts to find treatments for Alzheimer’s disease suffered blows in recent days, but many companies, scientists and investors are still optimistic that they can find a way to treat the memory-robbing ...
Roivant-backed health care technology company Datavant – formed late last year – has landed its first academic partner in Duke Clinical Research Institute (DCRI). Since the rollout of Datavant – on the heels of Roivant landing a $1.1 billion equity investment led by SoftBank Vision Fund – Datavant has integrated 150 datasets, aimed at using artificial intelligence to improve the time and success of clinical trials as well as their costs. "As I was founding Datavant, one of the first members of our advisory board was Frank Rockhold, a tireless advocate of clinical data sharing and a professor of biostatistics and bioinformatics at DCRI. Soon after meeting with other members of the DCRI leadership we each recognized the strong fit between our organizations and the potential for a partnership that would transform the drug development process,” Travis May, president and co-founder of Datavant, said in an email.
Axovant Sciences lost half of its market value Monday after it said a drug once intended to treat Alzheimer’s disease didn’t meet certain goals in recent studies.
Axovant Sciences watched its shares practically get halved in Monday’s session after the firm provided an update from a few of its midstage clinical trials.
The company flunked a mid-stage study testing the treatment on patients with dementia with Lewy bodies, three months after stopping the development of the drug, intepirdine, for treating Alzheimer's. Treatments for neurological disorders, like Alzheimer's and Parkinson's, could rake in blockbuster sales for drug developers but these drugs are expensive to develop and high failure rates have discouraged companies from pursuing their development. Pfizer Inc (PFE.N) said on Sunday it was abandoning research to find new drugs aimed at treating Alzheimer's and Parkinson's disease.
Shares of Axovant Sciences Ltd. plunged 46% toward a record low in premarket trade Monday, after the biopharmaceutical company said it would discontinue its intepirdine program for the treatment of dementia ...
Axovant Sciences Ltd said on Monday it would discontinue its intepirdine program after the experimental treatment failed in a mid-stage study on patients suffering from a type of dementia. Neither of the two doses of intepirdine given to patients with dementia with Lewy bodies resulted in improving their motor function, compared with patients given a placebo, Axovant said. In September, Axovant stopped testing the drug on patients suffering from Alzheimer's after a late-stage trial failure.